Skip to content

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Rob Schneider Stands Up Against The Globalist Vaccine Agenda

Show Me

Violent offences committed by men who self-identify as female ‘are distorting crime figures’

Show Me

Even kids-book writers feel forced to apologize for condemning anti-Semitism

Show Me

Amazon Calls for Higher Taxes on All Corporations Except Itself

Show Me

Conservative National Radio Host Wayne Allyn Root Announces Support for Black Reparations

Show Me

Ted Cruz introduces bill to ban vaccine database after Biden’s ‘door-to-door’ pledge

Show Me

California event center drops plans to host Gaetz, Greene’s ‘America First’ tour

Show Me

Is (Alleged) China-Defector Evidence Being Slow-Leaked? What Happens if Lab Leak is Confirmed?

Show Me

Another Female Customer Comes Forward After Person with “Beard and Penis” Exposed Himself to Her 6-Year-Old Daughter at Wi Spa in LA

Show Me

Former Bears linebacker Barkevious Mingo charged with indecency with child in Texas

Show Me

Illegal immigrant suspected of being a people-smuggling ‘kingpin’ is detained (London)

Show Me

Historic 102-Year-Old Lewis, Clark and Sacagawea Statue Toppled in Charlottesville — Too Offensive for Democrats

Show Me

Documentary to Explore CCP’s Thumb Print on Hollywood, Why it Threatens America

Show Me

U.K., Spain see COVID case spikes, but deaths stay flat

Show Me

President Donald Trump FULL SPEECH at CPAC 2021 in Dallas, TX 7/11/21

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded July 10, 2021 | Video: 48 Minutes 34 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded July 10, 2021 | Video: 48 Minutes 41 Seconds

Show Me

Massive Intimidation Underway Against Election 2020 Whistleblowers In Georgia

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 9, 2021 | Video: 48 Minutes 37 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 9, 2021 | Video: 48 Minutes 00 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded July 9, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Trump Sues Google, Facebook, Twitter Over Ban; 75 Lawmakers Urge: Reopen U.S.-Canada Border | Video: 18 Minutes 1 Second

Show Me

Former Obama Ethics Chief Slams Biden WH for Proposing Anonymous Buyers to Hunter’s Artwork: The ‘Opposite of Government Ethics’

Show Me

Confederate flag to fly again in rally at South Carolina Capitol

Show Me

Arizona Lawmaker Advises People to Put up ‘No Trespassing’ Signs to Deter Door-to-Door Vaccine Checks

Show Me

Tucker Carlson Torches Biden Admin For Vaccine Policies, Says They’re No Longer ‘Pro-Choice’

Show Me

Techno Fog Tracks Fusion GPS Recent Efforts to Avoid Litigation Discovery

Show Me

Failed mayoral candidate ambushed and murdered FBI agent: feds

Show Me

Pfizer says it is developing a Covid booster shot to deal with the delta variant

Show Me

North Dakota Sues the Biden Administration Over Oil and Gas Leases

Show Me

Health minister sparks row after claiming face masks only offer ‘marginal’ benefit in Covid fight 

Show Me

Journalist Nikole Hannah-Jones Joins Howard U Faculty After Tenure “Debacle” at UNC-Chapel Hill

Show Me

Speaker Pelosi’s Husband Made Millions in Transactions Related to Recent House Bills – Democrats Claim She Had No Involvement – Move Along

Show Me

The Real Story – OAN Exposing Election 2020 Zuckerbucks with Rep. Claudia Tenney

Show Me

Dr. Robert Malone, mRNA Vaccine Inventor, on the Bioethics of Experimental Vaccines and the ‘Ultimate Gaslighting’ | Video: 52 Minutes 32 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 8, 2021 | Video: 48 Minutes 29 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 8, 2021 | Video: 48 Minutes 24 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded July 8, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 7, 2021 | Video: 48 Minutes 52 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 7, 2021 | Video: 57 Minutes 57 Seconds

Show Me